ACB - Aurora Cannabis Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
0.5235
+0.0002 (+0.04%)
As of 02:34PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close0.5233
Open0.5281
Bid0.5245 x 1000
Ask0.5261 x 1400
Day's range0.5218 - 0.5420
52-week range0.4900 - 1.9400
Volume2,297,740
Avg. volume3,400,006
Market cap182.613M
Beta (5Y monthly)3.00
PE ratio (TTM)N/A
EPS (TTM)-6.0000
Earnings date14 Jun 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.85
  • CNW Group

    Aurora Cannabis to Host Third Quarter and Fiscal Year 2023 Investor Conference Call and File Related Year End Information

    Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, announced today that it has scheduled a conference call to discuss the results for its third quarter and full fiscal year 2023 on Wednesday, June 14, 2023 at 8:15 a.m. Eastern Time | 6:15 a.m. Mountain Time. The Company will report its financial results for the third quarter and full fiscal year 2023 before the opening of markets that same day. As a reminder, Fiscal 2023

  • CNW Group

    Aurora Celebrates Summer with New Innovation Launching Across Canada

    Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, is launching a fresh lineup of innovative products, available to patients on Aurora Medical and consumers, at retailers across the country this summer. The company's ever-expanding portfolio includes new 1mg format, snackable edibles, premium resin vape carts with big, bold flavour, and a true-to-form signature hash. New flower products include Chemango Kush, an original strain from Occo, Aurora's estee

  • CNW Group

    Aurora and Ethypharm Reaffirm their Commitment to Promote Access to Medical Cannabis for French Patients

    Aurora Europe GmbH, a subsidiary of Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), and Ethypharm are pleased to announce that they have once again been selected by the French General Directorate of Health (DGS) as exclusive suppliers of dried medical cannabis flower until the end of the French trial period. The trial has recently been extended until March 2024.

  • Motley Fool

    The Most Likely Scenario for Aurora Cannabis Stock Doesn't Look Good

    Aurora Cannabis (NASDAQ: ACB) has been struggling for years. The stock is trading down to well under $1 per share, and another reverse stock split is inevitable for the company. Aurora Cannabis' stock price fell 96% over the past three years.

  • Motley Fool

    Better Buy: Aurora Cannabis vs. Trulieve Cannabis

    One was once a favorite among cannabis investors, but the other could become the top cannabis contender.

  • Motley Fool

    This Troubled Stock Might Go Up in Smoke

    It's been roughly five years since Canada legalized cannabis, and it's been an unpleasant ride for investors in Aurora Cannabis (NASDAQ: ACB), one of Canada's leading growers and operators. The company became a penny stock after surging to over $120 per share in 2018. While some may hope for a tremendous comeback story, sometimes a business model just isn't good.

  • CNW Group

    Aurora Expands Medical Cannabis Portfolio in Germany: New flower varieties for patients with high THC needs

    Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, and a leading manufacturer and supplier of dried flower for medical patients worldwide, today announced the expansion of its portfolio in Germany with the launch of two new cannabis flower products for patients. Pedanios 27/1 FRG CA and Pedanios 29/1 SRD CA are dried cannabis flower with high tetrahydrocannabinol (THC) content. With these new therapeutic options now avai

  • Motley Fool

    Better Growth Stock: Aurora Cannabis vs. Tilray Brands

    Marijuana stocks have fallen out of favor in the last two years. The Canadian producers Aurora Cannabis (NASDAQ: ACB) and Tilray Brands (NASDAQ: TLRY) are two of the most popular marijuana companies. Aurora Cannabis has been investors' favorite among pot stocks for a while.

  • CNW Group

    Aurora Cannabis Partners with Strainprint to Empower Patients on their Cannabis Journey

    Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced the launch of a new tracking program designed to support and empower cannabis patients on their wellness journey.

  • CNW Group

    Aurora Introduces Fresh Innovation for Spring

    Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced a fresh lineup of innovative products. Coming soon to patients at Aurora Medical and to consumers at retail stores across the country, the company's expanded portfolio includes newly developed cultivars, strain-specific gummies and aromatic vapes. Flower products include two original strains from Occo, Aurora's esteemed breeding program: Pink Diesel '71 and Moon Berry.

  • CNW Group

    Aurora Repurchases ~$22 Million Principal Amount of Convertible Notes, Saving $1.2 Million in Annualized Interest Payments and Leaving ~$79 Million (US$59) of Notes Outstanding; Balance Sheet Remains Among Strongest in Canadian Cannabis Industry

    Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced that it has repurchased an aggregate of approximately $22.3 million (US$16.6 million) principal amount of its convertible senior notes ("Notes") in multiple transactions since the start of April 2023 at a total cash cost, including accrued interest, of $16.7 million (US$12.4 million) and $5.3 million (US$4.0 million), including accrued interest, satisfied

  • Motley Fool

    How Aurora Cannabis, Curaleaf, and SNDL Stack Up on 420 Day 2023

    April 20th has a special significance for the cannabis industry. Three of those companies have especially attracted investors' attention in recent years -- Aurora Cannabis (NASDAQ: ACB), Curaleaf Holdings (OTC: CURLF), and SNDL (NASDAQ: SNDL) (formerly known as Sundial Growers). Aurora Cannabis is the worst of the group, with its share price plunging more than 80%.

  • Motley Fool

    3 Former High-Flying Stocks Down 92% to 99% That Billionaire Investors Can't Stop Buying

    Despite losing most of their value, these former Wall Street darlings have been popular buys among billionaire money managers.

  • CNW Group

    Aurora and MedReleaf Australia Launch IndiMed Tempo 26, Further Strengthening Product Offerings for Medical Cannabis Patients

    Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, and MedReleaf Australia today announced the launch of IndiMed Tempo 26, a range of new higher THC dried cannabis products for qualified patients under the MedReleaf Concession Scheme (MCS). Tempo 26 will add to the portfolio of products available, giving doctors the ability to prescribe from a wider range of options for medical cannabis patients.

  • Motley Fool

    Which Canadian Cannabis Company Will Be the Next Takeover Target?

    The Canadian government's decision to license over 1,000 cannabis producers, along with its inability to rein in black market operators, has been an unmitigated disaster for the country's top legal cultivators. Despite billions of dollars being spent on state-of-the-art cultivation facilities, brick-and-mortar retail outlets, and virtual storefronts, Canada's largest cannabis companies have been losing money at an alarming rate due to a vast oversupply of product in the country. In turn, profit margins have cratered across the industry, spurring some notable cannabis companies like Aurora Cannabis (NASDAQ: ACB), SNDL, and Tilray Brands to diversify into non-cannabis businesses like alcohol and vegetables in an effort to become cash-flow-positive.

  • Motley Fool

    Better Buy: Aurora Cannabis vs. Green Thumb Industries

    Marijuana stocks have performed poorly over the last two years. Cannabis analytics firm BDSA estimates that global cannabis sales will reach $57 billion by 2026, a 13% annual growth forecast from $30 billion in 2021, with bulk of this growth expected to be driven by the Canadian and American markets. Investment opportunities seem lucrative, and investors with a higher risk appetite might stand to profit handsomely in the long run in this volatile industry.

  • Motley Fool

    Why Aurora Cannabis Stock Is Slumping Today

    Canadian marijuana company Aurora Cannabis (NASDAQ: ACB) is having another bad day. The pot seller's shares were down by a noteworthy 4.34% on moderate volume as of 2:05 p.m. ET on Monday. Since the start of the year, Aurora's stock has now shed 27.5% of its value, and the share price has fallen well below the Nasdaq's $1 bid requirement, triggering a noncompliance notice from the exchange last month.

  • CNW Group

    Aurora Repurchases ~$47 Million Principal Amount of Convertible Notes, Saving $2.6 Million in Annualized Interest Payments; Balance Sheet Remains Among Strongest in Canadian Cannabis Industry

    Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced that it has repurchased an aggregate of approximately $46.6 million (US$34.3 million) principal amount of its convertible senior notes ("Notes") at a total cost, including accrued interest, of $45.6 million (US$33.6 million) in cash, saving $2.6 million in annualized interest payments. Following completion of this repurchase, Aurora will have approximatel

  • Motley Fool

    Don't Buy the Hype: Aurora Cannabis' Transformation Hasn't Worked

    Restructuring and changes in strategy are moves that businesses often deploy when they're facing challenges and headwinds. While Aurora Cannabis (NASDAQ: ACB) has been slashing costs and changing its operations in recent years, the company isn't out of the woods by any stretch. Among the biggest moves that Aurora has made in recent years has been to shift its business more toward medical marijuana.

  • Motley Fool

    2 Reasons to Buy Aurora Cannabis and 1 Reason to Sell It

    Aurora Cannabis (NASDAQ: ACB) is one of the few Canadian cannabis retailers that is still seeing revenue growth, despite price compression and illegal sales negatively impacting the industry. The company is still losing money, but it appears to be edging its way toward profitability. Aurora's path to success includes branching out to international markets while focusing more on medical marijuana sales at home.

  • CNW Group

    Aurora Provides Update on Nasdaq Listing

    Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced receipt of a notification letter (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") dated March 24, 2023, advising that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) as the bid price of the Company's listed securities had closed at less than US$1.00 per share over the last 30 consecutive business days (the "Min

  • Motley Fool

    Why Pot Stocks Are Glowing Green Today

    With fears of economic turbulence receding, Aurora Cannabis, Canopy Growth, and Organigram rebounded from their Monday declines.

  • CNW Group

    Aurora Cannabis Announces Filing of Preliminary Base Shelf Prospectus

    Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced it has filed a new preliminary short form base shelf prospectus (the "Base Shelf Prospectus") with securities regulators in each of the provinces of Canada, except Quebec.

  • Motley Fool

    Here's How Aurora Cannabis Finally Posted an Adjusted EBITDA Profit

    Aurora Cannabis (NASDAQ: ACB) hit a long-awaited milestone in its most recent earnings results: adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) profitability. Here's a closer look at how Aurora achieved an adjusted EBITDA profit, and whether that should impact your decision to buy the stock or not. Since it's a non-GAAP (adjusted) number, a company can make adjustments to that number that it otherwise wouldn't be able to make to net income.

  • Motley Fool

    1 Trend for Cannabis Investors to Watch for in 2023

    The cannabis industry in Canada hasn't been in good shape for some time. Growth is almost nonexistent, profits are elusive, and stock prices of marijuana producers have been nosediving. What's particularly telling are the moves of two of the industry's leaders, Aurora Cannabis (NASDAQ: ACB) and Canopy Growth (NASDAQ: CGC).